Cholera Vaccines Market PPT: Overview, Dynamics, Trends, Segmentation, Application and Forecast to 2032
                     Global Cholera 
Vaccines Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the  la tes t  repor t  by  IMARC G roup ,  t i t l ed  "Chol era  Vacc ines Market :  
G loba l  I ndust ry  T rends ,  Share ,  S ize ,  Grow th ,  Opportun i ty  and  Forecast  2024-
2032, "  t he  g loba l  cho le ra  vacc ines  marke t  s i ze  reached  US$ 5 .4  M i l l i on  in  2023.
Report Cho le ra  i s  an  acu t e  in t es t i na l  d i sease  tha t  i s  genera l l y  caused by  the  consumpt ion  o f  con tamina t ed  wa te r  and  f ood .  I t  i s  spread by  the  V ib r i o  Cho le rae  
bac te r ia  t ha t  l eads  to  pa in  i n  t he  abdomen,  d ia r rhea,  nausea ,  vomi t ing  and  wat er -
Highlight and e lec t ro l y te  imba lance .  
Cho le ra  vacc ines  a re  e f fec t i ve  in  s t imu la t i ng  t he  p roduc t ion  o f  an t ibod ies  t ha t  a id  
Description i n  p reven t ing  the  d isease  among  ind i v idua ls .  W ide ly  p repared  us ing  the  l i ve  cho le ra- caus ing  bac te r i a  t o  a id  in  deve lop ing  immuni t y  aga ins t  t he  same,  t hese  
vacc ines  a re  d i rec t l y  in jec t ed  in t ramuscu la r l y  o r  i n t rade rma l l y  i n  t he  body .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/cho le ra- vacc ines-marke t / reques t samp le
Report Description
Global  Cho lera  Vacc ines  Market  T rends :
The g loba l  marke t  i s  p r ima r i l y  d r iven  by  the  esca la t ing  p reva lence  o f  cho le ra  among the  masses .  Th is  can  be  
a t t r ibu ted  to  the  poor  san i ta t i on  and  hyg iene  cond i t ions  in  ru ra l  and  geograph ica l l y  ex tended  a reas .  Moreover ,  
the  r i s ing  awareness  regard ing  the  ava i lab i l i t y  o f  cho le ra  vacc ines  among  the  masses  has p rope l led  the  p roduc t  
demand.  In  l i ne  w i th  th i s ,  numerous  in i t ia t i ves  under taken  by  severa l  government  agenc ies  and  non-government  
o rgan iza t ions  (NGOs)  ac ross  mu l t i p le  coun t r ies  fo r  conduc t ing  immun iza t ion  p rograms a re  p rov id ing  a  boos t  t o  
the  demand fo r  cho le ra  vacc ines .  
A long  w i th  th i s ,  t he  inc reas ing  inves tments  and  fund ing  by  pub l ic  and  p r iva te  agenc ies  fo r  conduc t ing  ex tens ive  
research  and  deve lopment  (R&D) ac t i v i t ies  a re  favorab ly  impac t ing  the  marke t .  O ther  fac to rs ,  i nc lud ing  the  
expand ing  hea l thcare  expend i tu re ,  a  cons ide rab le  inc rease  in  wa te r  po l lu t ion  leve ls ,  and  the  r i s ing  number  o f  
research  labo ra to r ies  and  d iagnos is  cen te rs ,  a re  a l so  pos i t i ve ly  in f luenc ing  the  marke t  g rowth .
Look ing  forward,  the  market  is  ant ic ipa ted to  reach  a  va lue  of  US$  13 .0  Mi l l ion  by  2032 .
V iew Repor t  TOC,  F igures  and  Tables :  h t tps: / /www. imarcgroup.com/cholera -vacc ines-marke t
Breakup by Vaccine Type:
• Whole Cel l  V. Cholerae O1 with Recombinant 
B-Subunit
• Ki l led Oral  O1 and O139
 
Breakup by Product:
Report • Dukoral
• Shanchol
Segmentation
• Vaxchora
• Euvichol  and Euvichol-Plus
• Others
Breakup by End User:
• Hospitals and Cl inics
• Research and Academic Laboratories
• Others
Breakup by Region:
• North America
Report • Asia-Pacifi c
Segmentation • Europe
• Latin America
• Middle East and Afr ica
• Astel las Pharma Inc.
• Cel ldex Therapeutics Inc.  (Avant 
Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
Competitive 
• Eubiologics Co. Ltd.
Landscape • Johnson & Johnson
with Key • Merck & Co. Inc.
• Pfi zer Inc.
Players
• PharmaChoice Canada Inc.
• Sanofi  S.A.
• Takeda Pharmaceutical  Company Limited
• Valneva SE
What was the size of the global cholera vaccines 
market in 2023?
What is the expected growth rate of the global 
cholera vaccines market during 2024-2032?
What are the key factors driving the global cholera 
vaccines market?
Key 
What has been the impact of COVID-19 on the 
Questions global cholera vaccines market?
Answered in What is the breakup of the global cholera vaccines market based on the vaccine type?
the Report What is the breakup of the global cholera vaccines 
market based on the product?
What is the breakup of the global cholera vaccines 
market based on the end user?
What are the key regions in the global cholera 
vaccines market?
Who are the key players/companies in the global 
cholera vaccines market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  C h o l e r a  V a c c i n e s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  V a c c i n e  T y p e
    6 . 1     W h o l e  C e l l  V .  C h o l e r a e  O 1  w i t h  R e c o m b i n a n t  B - S u b u n i t
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     K i l l e d  O r a l  O 1  a n d  O 1 3 9
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  P r o d u c t
    7 . 1     D u k o r a l
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
    7 . 2     S h a n c h o l
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     V a x c h o r a
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     E u v i c h o l  a n d  E u v i c h o l - P l u s
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     O t h e r s
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
Table of 8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     H o s p i t a l s  a n d  C l i n i c s
        8 . 1 . 1  M a r k e t  T r e n d s
Contents         8 . 1 . 2  M a r k e t  F o r e c a s t    8 . 2     R e s e a r c h  a n d  A c a d e m i c  L a b o r a t o r i e s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     O t h e r s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a t e s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        9 . 1 . 2  C a n a d a
           9 . 1 . 2 . 1  M a r k e t  T r e n d s
           9 . 1 . 2 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / c h o le r a -v a c c in e s - m a r ke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]